… to evaluate the efficacy and safety of anlotinib treatment in … in lung cancer as third-line or
more-line treatment in the real … the efficacy and toxicity of anlotinib after failure of prior treatment …

… Overall, our results and the evidence from earlier researches indicate that patients can
benefit from anlotinib treatment, regardless of EGFR status and previous EGFR target therapy. …

… can be easily performed, is safe, and can increase patient tolerance (19). In this study, 150
patients with advanced NSCLC were treated with anlotinib, and the efficacy and safety of the …

… from the beginning of anlotinib treatment to tumor progression or patient death. Overall
survival (OS) was defined as the time from the beginning of anlotinib treatment to patient death. …

… But in the real world, Anlotinib is also used in the second-line treatment of lung cancer. This
study aims to evaluate the efficacy of using Anlotinib in the second-line or further treatment of …

… for efficacy evaluation. The best overall response among the 118 patients was recorded
during anlotinib treatment. … in the 118 patients with NSCLC who received anlotinib treatment. …

… anlotinib combined with anlotinib maintenance may be a reliable, safe and feasible treatment
strategy for advanced NSCLC patients who fail first- or second-line treatment. Based on …

… In our study, no significant difference was seen in PFS between patients treated with anlotinib
alone and those treated with combination therapy, but the mOS of patients in combined …

… In the previously treated cohort in our study, anlotinib combination therapy improved survival
and tumor response to monotherapy. The ECOG PS of the enrolled patients was different …

… of anlotinib in SCLC at the frontline. Therefore, this study aimed to analyze real-world data
on anlotinib to evaluate whether anlotinib … therapy and second-line treatments, as well as …